Latest Commercialisation News

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.

Argosy Minerals has executed a spot sales contract for 60 tonnes of high-purity lithium carbonate from its Rincon project, marking a significant step in its lithium market engagement.

Andromeda Metals has launched a $5 million capital raising via a Placement, accompanied by Placement and Broker Options, to advance its flagship Great White Project and High Purity Alumina development.

Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.

Atomo Diagnostics has successfully closed a Share Purchase Plan and secured shareholder approval for a Tranche 2 Placement, raising a combined $1.53 million to support its ongoing operations.

Condor Energy has launched a comprehensive market and commercialisation study for its 1 trillion cubic feet Piedra Redonda gas discovery offshore Peru, aiming to chart a clear path toward development and partnerships.

Adherium Limited has announced a partially underwritten entitlement offer aiming to raise approximately A$4.5 million through the issuance of new shares and options at a significant discount. The capital raise is designed to accelerate patient onboarding and product development for its respiratory monitoring technology.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.

Neometals’ joint venture Reed Advanced Materials has signed a non-binding MoU with Rio Tinto to collaborate on advancing the ELi Process, a lithium hydroxide production technology promising significant cost and environmental benefits.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.